1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza Group Ltd. Appoints Marion Helmes as Independent Member of the Board of Directors, with Effect from May 5, 2022

01/26/2022 | 09:30am EDT

Marion Helmes has been appointed as an independent member of the Board of Directors of LONZA Group Ltd, with effect from 5 May 2022.


© S&P Capital IQ 2022
All news about LONZA GROUP AG
05/24Lonza Ties Up With Israel Biotech Fund On Biologics, Small Molecule Development, Manufa..
MT
05/24LONZA : and Israel Biotech Fund Collaboration Framework Agreement to Support Biologics and..
PU
05/23Switzerland's Lonza to Scale Up Inhalation Capabilities at US Site
MT
05/23LONZA : to Expand Inhalation Capabilities at Tampa Site
PU
05/18Lonza Opens New Facility for Kodiak Sciences' Retinal Diseases Drug
MT
05/09Lonza, ALSA Ventures Partner To Support Development Of Small Molecule Drug Candidates
MT
05/09LONZA GROUP AG : Ex-dividend day for Distribution from share premium account
FA
05/09LONZA GROUP AG : Ex-dividend day for final dividend
FA
05/06EuroAPI gains on market debut after spin-off from Sanofi
RE
05/05LONZA GROUP AG : Proxy Statments
CO
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Financials
Sales 2022 6 152 M 6 410 M 6 410 M
Net income 2022 1 064 M 1 108 M 1 108 M
Net cash 2022 423 M 441 M 441 M
P/E ratio 2022 38,7x
Yield 2022 0,59%
Capitalization 41 175 M 42 896 M 42 896 M
EV / Sales 2022 6,62x
EV / Sales 2023 5,90x
Nbr of Employees 16 218
Free-Float 98,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | LONN | CH0013841017 | MarketScreener
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 555,00 CHF
Average target price 796,79 CHF
Spread / Average Target 43,6%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Stefan Stoffel Head-Small Molecules Exclusive Synthesis Operation
Werner J. Bauer Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-27.15%42 618
MODERNA, INC.-48.00%54 740
IQVIA HOLDINGS INC.-28.41%38 497
SEAGEN INC.-13.67%25 649
ICON PUBLIC LIMITED COMPANY-30.17%17 688
CELLTRION, INC.-26.77%16 131